Polpharma Biologics has two streams of business, the development, and partnerships of our own molecules and providing top-quality contract development and manufacturing solutions to the industry to advance their biological pipeline of biosimilars and novel biologics.
Both our business streams are focused on our ambition to get effective and safe medicines to patients and we care as much about our partners molecules as we do our own. Work on both our own pipeline and those of our partners at multiple international centers of excellence in Poland and The Netherlands.
Biologics Portfolio & Partnerships
Polpharma Biologics has its own pipeline of biosimilar and novel therapeutics for out-licensing. We are focused on advancing and expanding our product portfolio to increase patient access to these much-needed therapies and are open to partnering with other organizations to co-develop or commercialize our biosimilars or novel therapeutics.
Our proprietary cell line development platform and highly efficient R&D workflows have set the stage for the development of six biosimilar candidates, with one finished the phase III and second started the phase I of clinical trials.